ACS Chemical Neuroscience p. 2624 - 2637 (2020)
Update date:2022-08-15
Topics:
Knutson, Daniel E.
Smith, Jodi L.
Ping, Xingjie
Jin, Xiaoming
Golani, Lalit K.
Li, Guanguan
Tiruveedhula, V. V. N. Phani Babu
Rashid, Farjana
Mian, Md Yeunus
Jahan, Rajwana
Sharmin, Dishary
Cerne, Rok
Cook, James M.
Witkin, Jeffrey M.
The need for improved medications for the treatment of epilepsy and chronic pain is essential. Epileptic patients typically take multiple antiseizure drugs without complete seizure freedom, and chronic pain is not fully managed with current medications. A positive allosteric modulator (PAM) of α2/3-containing GABAA receptors (5-(8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazole[1,5-α][1,4]diazepin-3-yl) oxazole or KRM-II-81 (8) is a lead compound in a series of imidazodiazepines. We previously reported that KRM-II-81 produces broad-based anticonvulsant and antinociceptive efficacy in rodent models and provides a wider margin over motoric side effects than that of other GABAA receptor PAMs. The present series of experiments was designed to fill key missing gaps in prior preclinical studies assessing whether KRM-II-81 could be further differentiated from nonselective GABAA receptor PAMs using the anticonvulsant diazepam (DZP) as a comparator. In multiple chemical seizure provocation models in mice, KRM-II-81 was either equally or more efficacious than DZP. Most strikingly, KRM-II-81 but not DZP blocked the development of seizure sensitivity to the chemoconvulsants cocaine and pentylenetetrazol in seizure kindling models. These and predecessor data have placed KRM-II-81 into consideration for clinical development requiring the manufacture of kilogram amounts of good manufacturing practice material. We describe here a novel synthetic route amenable to kilogram quantity production. The new biological and chemical data provide key steps forward in the development of KRM-II-81 (8) as an improved treatment option for patients suffering from epilepsy.
View MoreBuffett (China) Holding Co.,Ltd
Contact:4006570891
Address:
HANGZHOU FOREWIN PHARMA CO., LTD
Contact:+86-571-89053961
Address:hangzhou
Changzhou Hopschain Chemical Co.,Ltd
Contact:86-519-85528066
Address:Room 710, Unit A, Xingbei Development Mansion, Tongjiang Road, Changzhou City,213000, China
Zhejiang Hoshine Silicon Industry Co., Ltd.
Contact:86-573-89179966
Address:Zhapu Town, Pinghu City, Zhejiang, China
Taizhou volsen chemical Co., Ltd
website:http://www.volsenchem.com
Contact:+86-576-88869393
Address:Jiaojiang District, Taizhou, Zhejiang, China.
Doi:10.1021/acscatal.8b00010
(2018)Doi:10.1021/ja00225a018
(1988)Doi:10.1002/ejic.200600701
(2007)Doi:10.1021/bi00809a023
(1970)Doi:10.1007/BF00605209
(1990)Doi:10.1016/0022-328X(94)80127-4
(1994)